WO2011038110A3 - Methods of treating metabolic disease - Google Patents

Methods of treating metabolic disease Download PDF

Info

Publication number
WO2011038110A3
WO2011038110A3 PCT/US2010/049986 US2010049986W WO2011038110A3 WO 2011038110 A3 WO2011038110 A3 WO 2011038110A3 US 2010049986 W US2010049986 W US 2010049986W WO 2011038110 A3 WO2011038110 A3 WO 2011038110A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sirt6
metabolic disease
treating metabolic
expression
Prior art date
Application number
PCT/US2010/049986
Other languages
French (fr)
Other versions
WO2011038110A2 (en
Inventor
Raul Mostoslavsky
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Publication of WO2011038110A2 publication Critical patent/WO2011038110A2/en
Publication of WO2011038110A3 publication Critical patent/WO2011038110A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

It has been discovered that SIRT6 functions as a histone H3K9 deacetylase to control the expression of multiple glycolytic genes. Specifically, SIRT6 appears to function as a co-repressor of the transcription factor Hif1?, a critical regulator of nutrient stress responses. This invention relates generally to methods of reducing expression or activity of SIRT6 to reduce or inhibit hyperglycemia or obesity in a subject.
PCT/US2010/049986 2009-09-23 2010-09-23 Methods of treating metabolic disease WO2011038110A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24509809P 2009-09-23 2009-09-23
US61/245,098 2009-09-23
US25204409P 2009-10-15 2009-10-15
US61/252,044 2009-10-15

Publications (2)

Publication Number Publication Date
WO2011038110A2 WO2011038110A2 (en) 2011-03-31
WO2011038110A3 true WO2011038110A3 (en) 2011-10-20

Family

ID=43796483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/049986 WO2011038110A2 (en) 2009-09-23 2010-09-23 Methods of treating metabolic disease

Country Status (1)

Country Link
WO (1) WO2011038110A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810670A1 (en) 2010-09-10 2012-03-15 Neuronetrix Solutions, Llc Biomarker fusion system and method
US9650637B2 (en) 2012-01-24 2017-05-16 Bar-Ilan University Treatment of disease by modulation of SIRT6
US9422561B2 (en) 2012-01-24 2016-08-23 Bar-Ilan University Treatment of disease by modulation of SIRT6
US9833508B2 (en) * 2012-03-15 2017-12-05 Immix Biopharma, Inc. Cancer therapeutics
CN110151591A (en) 2012-10-09 2019-08-23 宝洁公司 The method of identification collaboration cosmetic combinations
JP6194003B2 (en) 2012-10-09 2017-09-06 ザ プロクター アンド ギャンブル カンパニー Method for identifying or evaluating beneficial agent and composition containing the same
ITMI20130647A1 (en) * 2013-04-19 2014-10-20 Univ Bologna Alma Mater COMPOUNDS WITH INHABITING ACTIVITIES ON SIRTUINES
ITMI20130646A1 (en) * 2013-04-19 2014-10-20 Univ Bologna Alma Mater CHINAZOLINDIONIC COMPOUNDS WITH INHABITING ACTIVITIES ON SIRTUINES
WO2023091783A1 (en) * 2021-11-22 2023-05-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Engineered immune cells with reduced sirt6 expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050204410A1 (en) * 2004-03-15 2005-09-15 Margaret Karow SIRT6 transgenic non-human animals and assay methods
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008138943A2 (en) * 2007-05-14 2008-11-20 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050204410A1 (en) * 2004-03-15 2005-09-15 Margaret Karow SIRT6 transgenic non-human animals and assay methods
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008138943A2 (en) * 2007-05-14 2008-11-20 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. H. WESTPHAL ET AL.: "A therapeutic role for sirtuins in diseases of aging?", TRENDS IN BIOCHEMICAL SCIENCES, vol. 32, no. 12, 2007, pages 555 - 560, XP022355518 *
RAUL MOSTOSLAVSKY ET AL.: "Genomic instability and aging-like phenotype in the absence of mammalian SIRT6.", CELL, vol. 124, no. 2, 2006, pages 315 - 329, XP002430108, DOI: doi:10.1016/j.cell.2005.11.044 *

Also Published As

Publication number Publication date
WO2011038110A2 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2011038110A3 (en) Methods of treating metabolic disease
WO2011083150A3 (en) Obesity small molecules
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2009089494A3 (en) Pharmaceutical compositions
MX2015008114A (en) Exendin-4 Derivatives.
SG11201601999UA (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
BRPI0919288A2 (en) combination therapy for treatment of diabetes and related conditions.
BR112012010261A2 (en) microcannula device, and methods for treating the supracoroidal space of an eye, for treating the posterior region of an eye, and for treating tissues within or adjacent to the supracoroidal space of an eye.
WO2012088519A3 (en) Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
MX2013005356A (en) Use of fluopyram for controlling nematodes in crops and for increasing yield.
EP2217062A4 (en) Multi-targeted rnai therapeutics for scarless wound healing of skin
WO2011163499A3 (en) Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
WO2013186240A3 (en) Exendin-4 peptide analogues
WO2008077092A8 (en) Combined effects of topiramate and ondansetron on alcohol consumption
WO2010080756A3 (en) Harmine derivatives for reducing body weight
NZ597510A (en) NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2011150007A3 (en) Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
WO2012058268A3 (en) Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
EP2271929A4 (en) Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
WO2010086828A3 (en) Agonist anti-trkb monoclonal antibodies
WO2014079545A8 (en) Thioether derivatives as protein kinase inhibitors
WO2009095517A3 (en) Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
ZA201301231B (en) Treatment of l-dopa,dopamine agonist and/or dopamine enhancer induced disorders
WO2011136573A3 (en) Yeast hydrolysate having obesity treatment effects and antioxidant activity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10819453

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10819453

Country of ref document: EP

Kind code of ref document: A2